Supply chain
Taiwan-Janssen Project picks 3 R&D units in 2019
Ambrose Huang, Taipei; Adam Hwang, DIGITIMES

Taiwan-Janssen Project, focusing on R&D of treating lung, rectal and colorectal cancers in 2019, has awarded grants to three academic/research units, according to Ministry of Science and Technology (MOST).

The three award recipients are: a team organized by Biomedical Technology and Device Research Laboratories (BTDRL) at government-sponsored Industrial Technology Research Institute; one from National Taiwan University (NTU); and one from Taipei Medical University (TMU).

Taiwan-Janssen Project is jointly sponsored by MOST, Ministry of Economic Affairs (MOEA) and Belgium-based Janssen Pharmaceutica, which is subsidiary of Johnson & Johnson.

Focusing on cancer treatment, the project calls for proposals from Taiwan-based academic and research organizations and then selects those with potential technologies for use in developing pharmaceuticals, diagnostic devices or medical materials.

Janssen will offer 3-year R&D subsidy of US$500,000 to the BTDRL team, while MOEA will also offer financial assistance at a certain percent of the amount.

The NTU team will be given US$60,000 from MOST for developing blood tests to identify epigenetic marks that could be signs of lung cancers in early stages, while the TMU teams will receive a MOST grant of US$40,000 for its research of using intestinal metagenomic sequencing to develop a vitro screening platform for people with high risks of rectal and colorectal cancers.

Janssen will offer 6-month technological counseling services for the NTC and TMU teams.

Awarding

Taiwan-Janssen Project's award ceremony
Photo: MOST

© 2020 DIGITIMES Inc. All rights reserved.
Please do not republish, publicly broadcast or publicly transmit content from this website without written permission from DIGITIMES Inc. Please contact us if you have any questions.